Latest 20-F annual reports

Aura Minerals Inc. filed an amendment to its 2025 annual report to include the Feasibility Study for the Matup Gold Project and Initial Assessment for Serrinhas and P Quente Targets in Brazil.

Aura Minerals Inc. has filed an amendment to its annual report to include the full technical report summary for its Matup Gold Project and related targets in Brazil.

Aura Minerals' Almas Project in Brazil reports significantly increased gold reserves and positive economics, driven by expanded operations and higher gold prices.

MicroAlgo Inc. reported a significant increase in net income for 2025 to $18.1 million, despite a 22.1% revenue decline, while navigating multiple share consolidations and a dual-class structure.

Scinai Immunotherapeutics reports continued operating losses and substantial doubt about its ability to continue as a going concern, despite growing CDMO revenues and strategic R&D advancements.

Nexera Technologies, formerly Jeffs Brands, reported a 19.3% revenue increase and reduced net loss in 2025, driven by HLS expansion and UK e-commerce, while navigating significant operational and market risks.

TOP Ships Inc. reported a 39% decrease in net income for 2025, alongside significant fleet refinancing activities and new orders for nine MR chemical/product oil tankers.

Innate Pharma reported continued net losses and a limited cash runway, prompting a strategic refocus on key clinical assets and a significant organizational restructuring.

ASE Technology Holding Co., Ltd. reported a significant increase in operating revenues and net profit for 2025, primarily fueled by robust demand in its advanced packaging and testing services, despite a slight decline in EMS business.

Aegon Ltd. files an amendment to its 2025 annual report, incorporating ASR Nederland N.V.'s audited financials which show a significant decrease in net result despite strong solvency and strategic acquisitions.

Afya Limited announced robust financial results for 2025, driven by significant revenue and net income growth, strategic acquisitions, and the maturation of its medical school seats.

NewGenIVF Group Limited reported a net income driven by non-cash gains in 2025, despite a significant decline in its core fertility services revenue and a widening operating loss, as it aggressively diversifies into digital assets and real estate.

Seanergy Maritime Holdings Corp. reported a significant decrease in net income for 2025, alongside strategic fleet expansion and active debt management.

GDEV Inc. reports a significant increase in net profit for 2025 despite declining revenues and bookings, driven by efficiency in user acquisition and strategic portfolio adjustments.

GeoPark Limited reported a significant drop in 2025 revenue and profit, offset by a strategic acquisition in Argentina's Vaca Muerta shale formation and a positive outlook for future production growth.

Tenaris reported resilient financial results in 2025 with $2.9 billion EBITDA and $2.0 billion net income, despite geopolitical disruptions and lower activity in key markets, while increasing dividends and share buybacks.

Nanobiotix's 2025 annual report highlights a significant revenue increase driven by a Janssen agreement amendment, new royalty financing, and ongoing clinical trial advancements for its lead product candidate, NBTXR3.

Ternium reports a significant drop in 2025 operating income amidst lower steel prices and U.S. trade measures, while advancing major expansion projects and cost-reduction initiatives.

Planet Image International Limited reported a net loss of $8.3 million for fiscal year 2025, driven by increased share-based compensation and lower gross profit, despite a 3.6% revenue increase.

SEALSQ Corp announced a 66% revenue increase in 2025, driven by semiconductor and PKI growth, alongside significant investments in post-quantum cryptography and strategic acquisitions, despite widening net losses.

Xtra-Gold Resources Corp. reported a significant increase in net income for 2025, driven by gold recovery and investment gains, while advancing exploration at its Kibi Gold Project in Ghana.

Intelligent Group Limited reported a substantial net loss of HK$18.18 million for fiscal year 2025, driven by share-based compensation and declining revenue, despite strategic acquisitions and capital raises.

B.O.S. Better Online Solutions Ltd. announced a significant increase in revenues and net income for fiscal year 2025, primarily fueled by heightened demand in the defense sector.

Strata Power Corporation reported a net loss of $38,587 for fiscal year 2025, with auditors raising substantial doubt about its ability to continue as a going concern due to limited cash and ongoing operational losses.

NeuroSense Therapeutics Ltd. reported positive long-term survival data for its lead ALS drug candidate, PrimeC, from its Phase 2b PARADIGM study, while also highlighting a substantial doubt about its ability to continue as a going concern without additional financing.

Allot Ltd. filed an amended annual report for 2025, correcting auditor report dates and disclosing a return to net income profitability and significant capital raise.

CytoMed Therapeutics Limited, a clinical-stage biopharmaceutical company, reported increased losses in 2025 as it advances multiple cell-based immunotherapy product candidates through preclinical and Phase I clinical trials.

Belite Bio announces highly significant Phase 3 DRAGON trial results for tinlarebant in STGD1, with an FDA NDA submission expected in Q2 2026, alongside ongoing GA trials and substantial capital raises.

RADCOM Ltd. announced robust financial results for fiscal year 2025, with significant revenue and net income increases, fueled by strong demand for its 5G and AI-driven network assurance solutions.

Check Point Software Technologies Ltd. reported a 6% increase in total revenues for 2025, reaching $2,725.4 million, driven by strong growth in security subscriptions and strategic AI-focused acquisitions.